143 related articles for article (PubMed ID: 32979164)
1. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
[TBL] [Abstract][Full Text] [Related]
2. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract][Full Text] [Related]
3. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
4. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
[TBL] [Abstract][Full Text] [Related]
5. EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
Paredes R; Kelly JR; Geary B; Almarzouq B; Schneider M; Pearson S; Narayanan P; Williamson A; Lovell SC; Wiseman DH; Chadwick JA; Jones NJ; Kustikova O; Schambach A; Garner T; Amaral FMR; Pierce A; Stevens A; Somervaille TCP; Whetton AD; Meyer S
Cell Death Dis; 2020 Oct; 11(10):878. PubMed ID: 33082307
[TBL] [Abstract][Full Text] [Related]
6. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
Kotaki R; Higuchi H; Ogiya D; Katahira Y; Kurosaki N; Yukihira N; Ogata J; Yamamoto H; Mohamad Alba S; Azhim A; Kitajima T; Inoue S; Morishita K; Ono K; Koyama-Nasu R; Kotani A
Int J Hematol; 2017 Dec; 106(6):811-819. PubMed ID: 28831750
[TBL] [Abstract][Full Text] [Related]
7. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
10. A critical role of epigenetic inactivation of miR-9 in EVI1
Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
[TBL] [Abstract][Full Text] [Related]
11. Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.
Saha HR; Kaneda-Nakashima K; Shimosaki S; Suekane A; Sarkar B; Saito Y; Ogoh H; Nakahata S; Inoue K; Watanabe T; Nagase H; Morishita K
Sci Rep; 2018 Sep; 8(1):13741. PubMed ID: 30214063
[TBL] [Abstract][Full Text] [Related]
12. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
13. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
[TBL] [Abstract][Full Text] [Related]
14. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
15. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
16. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
[TBL] [Abstract][Full Text] [Related]
18. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
[TBL] [Abstract][Full Text] [Related]
19. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
